Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 3/20 | 0.37 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613148 | 0.93 | PDE4B (0.40) | EHMT2PDE4BPDE4ACACNA1FCACNA1D | |
| SCHEMBL18423334 | 0.93 | PDE4B (0.40) | EHMT2PDE4BPDE4ACACNA1FCACNA1D | |
| SCHEMBL19273110 | 0.84 | KDM1A (0.42) | EHMT2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL19270712 | 0.81 | REN (0.38) | EHMT2PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL19252796 | 0.81 | CYP2C9 (0.36) | CACNA1FCACNA1DCACNA1SCACNA1CHTR2C | |
| SCHEMBL29613292 | 0.81 | CYP2C9 (0.36) | CACNA1FCACNA1DCACNA1SCACNA1CHTR2C | |
| SCHEMBL28767997 | 0.77 | PDE4A (0.42) | EHMT2PDE4BPDE4ACACNA1FCACNA1D | |
| SCHEMBL19953407 | 0.75 | FPR2 (0.32) | EHMT2 | |
| SCHEMBL19252806 | 0.75 | HTR2C (0.42) | PDE4BPDE4APDE4CPDE4DREN | |
| SCHEMBL18423921 | 0.75 | PDE4A (0.50) | PDE4BPDE4APDE4CPDE4DKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071447-B | Tetracyclic pyridinone compounds as antiviral agents | 诺华股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3416946-B1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| EP-3416946-B1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-20200270265-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-20200270265-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| EP-3416946-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-10093673-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2018-10-09 | — | — | US | disclosed |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9845325-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-9845325-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-9845325-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-08-24 | — | — | US | disclosed |
| WO-2017140821-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140821-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270265-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | PNPO, HAVCR2, TYMP | EHMT2 4692/4885PDE4B 1845/4885PDE4A 2146/4885 |
| US-10093673-B2 | Tetracyclic pyridone compounds as antivirals | PNPO, HAVCR2, TYMP | EHMT2 4692/4885PDE4B 1845/4885PDE4A 2146/4885 |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | PNPO, HAVCR2, TYMP | EHMT2 4692/4885PDE4B 1845/4885PDE4A 2146/4885 |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | PNPO, HAVCR2, TYMP | EHMT2 4692/4885PDE4B 1845/4885PDE4A 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.